404 Not Found
nginx/1.6.1Financial Fund News on July 8 Xinghua Innovation Medical 6-month Holding Period Hybrid Initiated Securities Investment Fund (Abbreviation: Xinghua Innovation Medical 6-month Holding Hybrid A, code 013920) On July 7, the net value fell by 2.17%, attracting investors' attention. The current net value of fund unit is 0.9054 yuan, and the cumulative net value is 0.9054 yuan.
Xinghua Innovation Medical's 6-month return on Mixed A Fund has been -9.46% since its establishment, -9.24% since this year, and 11.20% in the past month.
This fund has distributed 0 dividends since its establishment, with a cumulative dividend amount of 0 billion yuan. The fund is currently open for subscription. The fund manager of
is Leng Wenpeng. He has managed the fund since November 30, 2021, with a return of -9.46% during his tenure. The latest fund periodic report of
shows that the fund holds heavy positions in Zhifei Biotechnology ( holds proportion of 6.94%), China Traditional Chinese Medicine (position proportion of 6.39%), Cardiovascular Medical (position proportion of 5.66%), Furui Shares (position of 5.66%) proportion 4.56%), Boya Biotechnology (position proportion 3.91%), Pluto Pharmaceuticals (position proportion 3.89%), Kindly (position proportion 3.33%), Yingke Medical (position proportion 3.14%), Livzon Group (position ratio 2.83%), JD Health (position ratio 2.76%).
fund investment strategy and operation analysis during the reporting period
During the reporting period, the market overall showed a sharp unilateral downward trend, affected by factors such as market decline, medical insurance negotiations, centralized drug procurement, obstruction of innovative drugs going overseas, and high early valuations. , the pharmaceutical industry also experienced a large decline, but sectors related to traditional Chinese medicine that benefited from favorable policies, antigen that benefited from new crown detection, and new crown specific drugs for treatment performed better.
htmlIn May, affected by the pessimistic expectations of medical insurance negotiations and centralized purchasing price cuts, the market lacked confidence in the innovation prospects of the pharmaceutical industry. The high valuations due to the early optimism needed to be digested. The pharmaceutical industry generally fell, and the decline was higher than the market. html In February, after the early release of pessimism, the pharmaceutical industry stabilized in stages. Among them, vaccines, traditional Chinese medicine, and medical devices rebounded first, while CXO and medical services performed weakly. htmlIn March, the pharmaceutical industry continued to stabilize and rebound, with vaccines, traditional Chinese medicines, and COVID-19 specific drugs leading the gains, while innovative drugs, medical devices, and medical services (non-CXO) performed weakly, and the COVID-19 theme became more popular.This fund focuses on the fields of innovative drugs, innovative devices, innovative services and innovative technologies, focusing on industry giants with rich product pipelines, complete business layout, outstanding innovation capabilities and rapid internationalization process, as well as specialization, special new related segment competitions At the same time, it continues to actively pay attention to and study the potential investment opportunities brought by new policy orientations (such as traditional Chinese medicine, rehabilitation, pharmaceutical manufacturing, etc.), and pays attention to the risk-return balance of the portfolio, giving priority to valuation and expected income performance growth. Robust varieties with matching speed. Against the background of the sharp decline in the market and pharmaceutical industry in the first quarter, the fund performance was poor because the portfolio position was at a high level.
Looking to the future, the biggest challenges for the pharmaceutical industry mainly come from changes in the COVID-19 epidemic and the impact of medical insurance policies. It still needs to wait for signals of positive changes, and it will also take some time to repair the market's pessimistic expectations for medical innovation. However, short-term setbacks have not changed the mid- to long-term growth prospects of medicine, especially the innovative medical field. The darkness before dawn is the most painful. What is needed most is persistence and taking advantage of the opportunity of the market to deploy high-quality companies.
thanks the holders for their support. Your trust is the biggest motivation for us to move forward. We will continue to be diligent and responsible, work hard and enterprising, never forget our original intention, be loyal to our trust, and dedicate rewards for trust.
Fund performance during the reporting period
